Category: Regions

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the appointment of Soumya Chandramouli as Chief Financial Officer (CFO).

Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare sectors with revenues of circa €500M, where she led a team of 50+ staff across multiple entities in North America and EMEA. Soumya recently contributed to a €93M private equity backed fundraising of a spin-off in the life sciences sector in Belgium.

Soumya’s experience in a globally deployed organization will be vital in supporting Novadip as it aims to become a commercial company with NVD003, its first autologous product, in the US, EU and Japanese markets in 2027, to address rare pediatric indications including Congenital Pseudarthrosis of the Tibia (CPT).

Novadip is planning a €50M Series C funding round with the aim of conducting two phase 3 trials with NVD003 and a Phase 2b/3 trial with NVDX3. The first patient in the NVD003 Phase 3 study in CPT will be enrolled in Q2, 2025. With access to the FDA’s Priority Review Voucher (>$150M), NVD003 could generate significant revenues. From 2027 to 2029, the commercial deployment of NVD003 for CPT will be associated with an increase in its clinical indications. Novadip’s Phase 2b/3 trial with NVDX3, its allogenic cell-derived product, will target spine fusion and trauma indications. The company is also developing its cell-free platform for the treatment of bone tumors and skin healing.

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, a clinical stage company focused on developing novel therapies for metabolic and endocrine disorders.